Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

PProMIS Neurosciences Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
P

ProMIS Neurosciences Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
    Sep 1, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
    Sep 1, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
    Aug 13, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
    Aug 13, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
    Aug 3, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
    Aug 3, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
    Jul 28, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
    Jul 28, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
    Jul 27, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
    Jul 27, 2026ProMIS Neurosciences, Inc. (PMN) Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$13.80Close · Sep 22, 2026